JAK2 and myeloproliferative disorder: Inhibitors of the tyrosine kinase activity of JAK2 have proven efficacious in reducing splenomegaly and improving constitutional symptoms in patients with MPN, particularly MF; however, they do not selectively target the mutated clone and their potential activity is constrained by myelotoxicity, indicating that novel therapeutic strategies should be sought.